CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 24, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, will release its second quarter financial results on Tuesday, July 31, 2007 before the market opens. The Company will also hold a conference call on July 31st at 10:00 A.M. Eastern time to discuss its financial results, the progress of CUDC-101 and other multi-target inhibitors that Curis is developing under its Targeted Cancer Drug Development Platform, Curis' Hedgehog-based product development programs under collaboration with Genentech and Wyeth, as well as additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (888) 680-0890 from the United States or Canada or (617) 213-4857 from other locations, shortly before 10:00 A.M. EDT. The conference ID number is 63684401. Replay will be available approximately two hours after the completion of the call and through Tuesday, August 14, 2007. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 99976023.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit www.curis.com.
CONTACT: Michael P. Gray
CFO & COO